🔬 Drug Delivery & Formulation

1. Lipid nanoparticles as mRNA delivery systems - post-COVID boom in literature, tons of recent data
2. Exosome-based drug delivery - emerging, rapidly growing field with plenty of review gaps
3. 3D-printed personalized dosage forms - highly novel, good for a pharmacy-focused angle
4. Mucoadhesive drug delivery for oral mucosal diseases - well-established base + recent innovations

💊 Pharmacology & Therapeutics

1. GLP-1 receptor agonists beyond diabetes: obesity, NAFLD, cardiovascular protection - massive literature surge (semaglutide, tirzepatide era)
2. Pharmacogenomics in anticoagulant therapy (warfarin/DOACs) - clinically relevant, data-rich
3. Repurposing metformin: anticancer, anti-aging, neuroprotective roles - huge body of evidence
4. Role of the gut microbiome in drug metabolism and pharmacokinetics - interdisciplinary, growing fast

🧬 Emerging Therapeutics

1. CRISPR-based therapeutics: current approvals and pipeline - Casgevy approval gives you a real anchor
2. Antibody-Drug Conjugates (ADCs) in oncology - 12+ FDA approvals now, rich clinical data
3. Small interfering RNA (siRNA) drugs: mechanisms and clinical applications - inclisiran, patisiran, etc.

🌿 Natural Products & Nutraceuticals

1. Nanoformulations of curcumin: overcoming bioavailability barriers - extensive literature, pharmacy-relevant
2. Phytochemicals as P-glycoprotein inhibitors in drug resistance - good mechanistic + clinical angle

🏥 Clinical Pharmacy / Public Health

1. Antimicrobial stewardship programs in hospital settings - very publishable, policy-relevant
2. Drug-induced liver injury (DILI): mechanisms, biomarkers, and prediction - solid literature base
3. Medication adherence technologies: smart packaging, apps, digital therapeutics - growing and fundable topic

My Top Picks for a Pharmacy Student

• Pick a topic where a PubMed search returns 200-500 papers in the last 5 years - enough material but not overwhelming
• Avoid topics with existing Cochrane or high-impact meta-analyses from 2024-2025 unless you have a new angle
• Choose something aligned with your pharmacy specialization (clinical, industrial, community)

📊 PubMed Literature Volume Comparison (2021-2026)

What This Tells You

1. Lipid Nanoparticles / mRNA (873 papers) - Proceed with caution

• Rich material, high-impact journals (ACS Nano, Nature, Nat Rev Drug Discov)
• Problem: The field is saturated with reviews. You need a very narrow angle to stand out - e.g., "LNPs for cancer immunotherapy specifically" or "organ-selective LNP targeting"
• Papers like PMID 34181394 and 38307296 are landmark reviews already covering the broad topic

2. Antibody-Drug Conjugates (1,408 papers) - Too saturated for a student

• Enormous literature with RCTs in NEJM (2026!), JCO, Cancer Cell
• Multiple high-quality Nat Rev Drug Discov reviews already exist (PMID 37308581)
• Hard to add value unless you focus on one specific ADC or cancer type

3. GLP-1 Agonists beyond diabetes (69 papers) - Best pick 🏆

• Ideal volume - enough material to write a solid review, not so much you're overwhelmed
• Mix of RCTs, guidelines (AASLD/AACE), and mechanistic reviews
• Rapidly evolving: tirzepatide, retatrutide, semaglutide for MASLD are all very recent (2024-2026 papers)
• Clear gap: Most reviews focus on diabetes; fewer cover the full spectrum of obesity + NAFLD/MASLD + cardiovascular protection together
• Niche you can own: "GLP-1/GIP dual agonists in metabolic-associated steatotic liver disease (MASLD): evidence and future directions"

My Recommendation